Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas
Some people with certain lymphomas survive ten years cancer-free after CAR T-cell therapy, with no relapses occurring after five years.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Disparate privacy risks from medical AI
Researchers identified that medical AI systems expose underrepresented patient groups to disproportionate privacy risks, prompting urgent safeguards.
Automated reanalysis of genomic data for rare disease diagnostics at scale
Monthly reanalysis of genetic data using updated evidence identified rare disease diagnoses in over 5% of previously undiagnosed patients.
Multimodal blood based proteomic profiling reveals insights into…
Blood protein patterns may help predict which melanoma patients will respond to immunotherapy and which may experience treatment-related side effects.
Effects of exercise and liraglutide on vascular health and…
Exercise combined with the medication liraglutide improved measures of blood vessel health more effectively than either approach alone.